Lipegfilgrastim

Phase 3Protein / enzyme

Merck & Co.

Lipegfilgrastim is one of 94 small molecule programs targeting Neutropenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Breast CancerActive, not recruiting

RhabdomyosarcomaActive, not recruiting

NeutropeniaPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

RhabdomyosarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Lipegfilgrastim

Merck & Co.

Phase 3

1 3

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 6

Tianeptine

Pfizer

Preclinical

1 7

Ablavar

LLantheus Medical Imaging

Preclinical

2 8

Citalopram Hydrobromide

TTorrent Pharmaceuticals Limited

Preclinical

1 9

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 10

Leronlimab

CCytoDyn, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rhabdomyosarcoma1 trial

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01585649·21 enrolled

ART1 trial

PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02306915·48 enrolled

Neutropenia1 trial

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

Completed· Teva logo

Teva·Phase 3·NCT02044276·101 enrolled

Breast Cancer1 trial

Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

Completed·—··NCT02527317·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lipegfilgrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipegfilgrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipegfilgrastim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Lipegfilgrastim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rhabdomyosarcoma1 trial

ART1 trial

Neutropenia1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News